ViewRay
Advanced radiation therapy technology for the treatment of cancer.
Launch date
Employees
Market cap
€886
Enterprise valuation
€749 (Public information from Aug 2023)
Share price
$0.025 VRAY
Oakwood Ohio (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 34.0m | 81.0m | 88.0m | 57.0m | 70.0m | 102m | 135m |
| % growth | - | 138 % | 9 % | (35 %) | 23 % | 46 % | 32 % |
| EBITDA | (46.0m) | (67.0m) | (108m) | (99.0m) | (98.0m) | (100m) | (94.0m) |
| % EBITDA margin | (135 %) | (83 %) | (123 %) | (174 %) | (140 %) | (98 %) | (70 %) |
| Profit | (72.0m) | (76.0m) | (120m) | (108m) | (110m) | (107m) | (92.0m) |
| % profit margin | (212 %) | (94 %) | (136 %) | (189 %) | (157 %) | (105 %) | (68 %) |
| EV / revenue | 18.0x | 5.8x | 5.0x | 8.4x | 11.8x | 7.5x | - |
| EV / EBITDA | -13.3x | -7.0x | -4.0x | -4.8x | -8.4x | -7.6x | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $3.0m | Series A | |
$25.0m | Series B | ||
$20.0m | Series C | ||
| N/A | N/A | Debt | |
$10.0m | - | ||
$45.0m | Series C | ||
$15.0m | - | ||
$30.0m | - | ||
| N/A | N/A | Series C | |
| N/A | N/A | Seed | |
$50.0m | Private Placement VC | ||
$26.7m | Private Placement VC | ||
| N/A | N/A | IPO | |
$14.0m | Post IPO Equity | ||
$26.1m | Post IPO Equity | ||
| N/A | N/A | Post IPO Equity | |
| N/A | N/A | Post IPO Equity | |
| N/A | $173m | Post IPO Equity | |
$56.0m | Post IPO Debt | ||
$36.0m | Post IPO Equity | ||
* | N/A | $80.5m | Secondary |
* | $125m | Post IPO Debt | |
| Total Funding | €204m | ||
Related Content
Recent News about ViewRay
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.